TARA - Protara Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

TARA is currently covered by 3 analysts with an average price target of $41.95. This is a potential upside of $38.68 (1182.87%) from yesterday's end of day stock price of $3.27.

Protara Therapeutics's activity chart (see below) currently has 13 price targets and 21 ratings on display. The stock rating distribution of TARA is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 12.5% with an average time for these price targets to be met of 123.75 days.

Highest price target for TARA is $23, Lowest price target is $23, average price target is $23.

Most recent stock forecast was given by ANDREW FEIN from HC WAINWRIGHT on 05-Mar-2025. First documented stock forecast 21-Sep-2016.

Best performing analysts who are covering TARA - Protara Therapeutics:

Swayampakula Ramakanth Leland Gershell Jason Mccarthy Andrew Fein

Currently out of the existing stock ratings of TARA, 9 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$23

$19.76 (609.88%)

$23

2 months 7 days ago
(05-Mar-2025)

0/3 (0%)

$19.08 (486.73%)

Buy

9 months 1 days ago
(11-Aug-2024)

0/3 (0%)

$26.43 (349.14%)

Buy

2 years 9 months 3 days ago
(09-Aug-2022)

2/4 (50%)

$14 (9.59%)

495

Buy

$200

6 years 1 months 14 days ago
(28-Mar-2019)

0/2 (0%)

$95.2 (117.68%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is TARA (Protara Therapeutics) average time for price targets to be met?

On average it took 123.75 days on average for the stock forecasts to be realized with a an average price target met ratio 12.5

Which analyst has the current highest performing score on TARA (Protara Therapeutics) with a proven track record?

SWAYAMPAKULA RAMAKANTH

Which analyst has the current lower performing score on TARA (Protara Therapeutics) with a proven track record?

ANDREW FEIN

Which analyst has the most public recommendations on TARA (Protara Therapeutics)?

Swayampakula Ramakanth has 13 price targets and 11 ratings on TARA

Which analyst is the currently most bullish on TARA (Protara Therapeutics)?

Andrew Fein with highest potential upside - $19.76

Which analyst is the currently most reserved on TARA (Protara Therapeutics)?

Leland Gershell with lowest potential downside - -$0

Protara Therapeutics in the News

Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

Reported positive interim results demonstrating durable responses in the ongoing Phase 2 ADVANCED-2 trial of TARA-002 in NMIBC Results from planned interim analysis of approximately 25 six-month evaluable BCG-Unresponsive patients expected by the end of 2025 Dosing of first patient in THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support expected...

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to six newly-hired employees. The independent members of Protara’s Board...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?